Imidazolines

01/01/2019 - "Imidazoline-based small molecule inhibitors of p53-MDM2 interaction intended for the treatment of p53 wild-type tumors are the promising structures for design of anticancer drugs. "
09/15/2011 - "Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53-MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. "
11/03/2006 - "This is supported by the potent activation of P53 in tumor cells by Nutlin, a cis-imidazoline that inhibits the Hdm2-P53 interaction. "
10/16/2006 - "[Imidazoline I(2) receptors as a possible marker for malignancy in human glial cell tumours]."
10/01/2006 - "New alkyl imidazoline derivatives have been synthesized as potential anti-cancer agents. "

01/01/2001 - "Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?"
05/01/1998 - "[New trends in the treatment of arterial hypertension: identification of the I1 receptor and the pharmacology of imidazoline]."
01/01/1997 - "Imidazoline I1 receptor agonists: new data on hypertension and related pathologies: introduction."
08/01/1996 - "Imidazoline-preferring receptors are important in the pathophysiology of hypertension. "
07/01/1980 - "[Use of imidazoline derivatives in patients with arterial hypertension]."

10/01/2016 - "[Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine]."
01/01/2006 - "We sought to determine the possible mechanism for the lipid-lowering actions of imidazolines in a model of metabolic Syndrome X, the spontaneously-hypertensive obese (SHROB) rat. "
01/01/2013 - "Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study."
01/01/2006 - "Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X."
01/01/2005 - "In previous studies, the I1 imidazoline specific agonist rilmenidine effectively lowered office blood pressure (BP) in patients with metabolic syndrome, improved glucose metabolism and did not demonstrate unfavourable effects on plasma lipids. "

09/01/1997 - "In rat experiments new imidazoline derivatives caused a pain-relieving effect and inhibited a rise in arterial pressure in pain. "
12/15/2015 - "This study compares the effects of the imidazoline compounds 1, 2, and 3 on morphine tolerance in an animal model of inflammatory pain in the rat. "
09/01/1997 - "[Study of analgesic effect of novel imidazoline derivatives and their effect on arterial pressure during pain]."
11/01/2011 - "These data suggest that drugs acting on imidazoline I(2) receptors may be useful either alone or in combination with opioids for the treatment of pain."
09/01/1997 - "The prospects of directed chemical modification of imidazoline derivatives to obtain new analgesics capable of reducing the undesirable hemodynamic manifestations of pain are discussed."

09/10/2017 - "Comparative pharmacodynamic analysis of imidazoline compounds using rat model of ocular mydriasis with a test of quantitative structure-activity relationships."
04/01/2017 - "The imidazoline compounds may produce mydriasis after systemic administration to some species (rats, cats, and mice). "
01/15/2005 - "These results suggest that imidazoline I(1) receptors are not functionally involved in the rat clonidine mydriasis model and support this in vivo system as a useful model for studies of alpha(2)-adrenoceptors."
04/01/2017 - "Are Alpha-2D Adrenoceptor Subtypes Involved in Rat Mydriasis Evoked by New Imidazoline Derivatives: Marsanidine and 7-Methylmarsanidine?"
01/01/2013 - "However, it became obvious later that clonidine-like imidazol(in)e adrenoceptor agonists which produced mydriasis in rats, exhibit also a high affinity for imidazoline I1-receptors. "